A moderate elevation of circulating levels of IGF-I does not alter ErbB2 induced mammary tumorigenesis

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Dearth, Robert K ^a,b   Kuiatse, Isere ^a   Wang, Yu Fen ^a   Liao, Lan ^a   Hilsenbeck, Susan G ^a   Brown, Powel H ^a   Xu, Jianming ^a   Lee, Adrian V ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS PAN AMERICAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; SOMATOMEDIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BREAST ADENOCARCINOMA; BREAST CANCER; BREAST CARCINOGENESIS; BREAST DEVELOPMENT; BREAST METASTASIS; CANCER GROWTH; CANCER SIZE; CONTROLLED STUDY; FEMALE; GENOTYPE; GROWTH RATE; HETEROZYGOTE; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PUBERTY; TISSUE SECTION; TRANSGENICS; WILD TYPE; ANIMAL; C57BL MOUSE; CELL TRANSFORMATION; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; SIGNAL TRANSDUCTION; TRANSGENE; TRANSGENIC MOUSE; UDDER;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE EXPRESSION REGULATION; INSULIN-LIKE GROWTH FACTOR I; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TRANSGENES;

EID: 80052025376     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-377     Document Type: Article

References (38)

1. Sachdev D, Yee D. Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer. J Mammary Gland Biol Neoplasia 2006, 11:27-39. 10.1007/s10911-006-9010-8, 16947084.
2. Lann D, LeRoith D. The role of endocrine insulin-like growth factor-I and insulin in breast cancer. J Mammary Gland Biol Neoplasia 2008, 13:371-379. 10.1007/s10911-008-9100-x, 19030972.
3. Renehan AG, Harvie M, Howell A. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. Endocr Relat Cancer 2006, 13:273-278. 10.1677/erc.1.01219, 16728563.
4. Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ. Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1998, 7:1133-1144.
5. Byrne C, Hankinson SE, Pollak M, Willett WC, Colditz GA, Speizer FE. Insulin-like growth factors and mammographic density. Growth Horm IGF Res 2000, 10(Suppl A):S24-25.
6. Wagner K, Hemminki K, Grzybowska E, Klaes R, Burwinkel B, Bugert P, Schmutzler RK, Wappenschmidt B, Butkiewicz D, Pamula J, et al. Polymorphisms in genes involved in GH1 release and their association with breast cancer risk. Carcinogenesis 2006, 27:1867-1875. 10.1093/carcin/bgl036, 16606630.
7. Lagiou P, Hsieh CC, Lipworth L, Samoli E, Okulicz W, Troisi R, Xu B, Hall P, Ekbom A, Adami HO, Trichopoulos D. Insulin-like growth factor levels in cord blood, birth weight and breast cancer risk. Br J Cancer 2009,
8. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001, 93:1852-1857. 10.1093/jnci/93.24.1852, 11752009.
9. Camirand A, Lu Y, Pollak M. Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Med Sci Monit 2002, 8:BR521-526.
10. Pollak MN. Endocrine effects of IGF-I on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention. Breast Cancer Res Treat 1998, 47:209-217. 10.1023/A:1005950916707, 9516077.
11. Kleinberg DL, Feldman M, Ruan W. IGF-I: an essential factor in terminal end bud formation and ductal morphogenesis. J Mammary Gland Biol Neoplasia 2000, 5:7-17. 10.1023/A:1009507030633, 10791764.
12. Stull MA, Richert MM, Loladze AV, Wood TL. Requirement for IGF-I in epidermal growth factor-mediated cell cycle progression of mammary epithelial cells. Endocrinology 2002, 143:1872-1879. 10.1210/en.143.5.1872, 11956170.
13. Ruan W, Kleinberg DL. Insulin-like growth factor I is essential for terminal end bud formation and ductal morphogenesis during mammary development. Endocrinology 1999, 140:5075-5081. 10.1210/en.140.11.5075, 10537134.
14. Bonnette SG, Hadsell DL. Targeted disruption of the IGF-I receptor gene decreases cellular proliferation in mammary terminal end buds. Endocrinology 2001, 142:4937-4945. 10.1210/en.142.11.4937, 11606462.
15. Wu Y, Sun H, Yakar S, LeRoith D. Elevated levels of insulin-like growth factor (IGF)-I in serum rescue the severe growth retardation of IGF-I null mice. Endocrinology 2009, 150:4395-4403. 10.1210/en.2009-0272, 2819739, 19497975.
16. Cannata D, Lann D, Wu Y, Elis S, Sun H, Yakar S, Lazzarino DA, Wood TL, Leroith D. Elevated circulating IGF-I promotes mammary gland development and proliferation. Endocrinology 2010, 151:5751-5761. 10.1210/en.2010-0792, 20926579.
17. Lee AV, Taylor ST, Greenall J, Mills JD, Tonge DW, Zhang P, George J, Fiorotto ML, Hadsell DL. Rapid induction of IGF-IR signaling in normal and tumor tissue following intravenous injection of IGF-I in mice. Horm Metab Res 2003, 35:651-655.
18. Divisova J, Kuiatse I, Lazard Z, Weiss H, Vreeland F, Hadsell DL, Schiff R, Osborne CK, Lee AV. The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res Treat 2006, 98:315-327. 10.1007/s10549-006-9168-1, 16541323.
19. Yang XF, Beamer WG, Huynh H, Pollak M. Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation. Cancer Research 1996, 56:1509-1511.
20. Wu Y, Cui K, Miyoshi K, Hennighausen L, Green JE, Setser J, LeRoith D, Yakar S. Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res 2003, 63:4384-4388.
21. Liao L, Dearth RK, Zhou S, Britton OL, Lee AV, Xu J. Liver-specific overexpression of the insulin-like growth factor-I enhances somatic growth and partially prevents the effects of growth hormone deficiency. Endocrinology 2006, 147:3877-3888. 10.1210/en.2005-1537, 16709615.
22. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998, 351:1393-1396. 10.1016/S0140-6736(97)10384-1, 9593409.
23. Rowse GJ, Ritland SR, Gendler SJ. Genetic modulation of neu proto-oncogene-induced mammary tumorigenesis. Cancer Res 1998, 58:2675-2679.
24. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 1992, 89:10578-10582. 10.1073/pnas.89.22.10578, 50384, 1359541.
25. Williams JM, Daniel CW. Mammary ductal elongation: differentiation of myoepithelium and basal lamina during branching morphogenesis. Dev Biol 1983, 97:274-290. 10.1016/0012-1606(83)90086-6, 6852366.
26. Lee AV, Zhang P, Ivanova M, Bonnette S, Oesterreich S, Rosen JM, Grimm S, Hovey RC, Vonderhaar BK, Kahn CR, et al. Developmental and hormonal signals dramatically alter the localization and abundance of insulin receptor substrate proteins in the mammary gland. Endocrinology 2003, 144:2683-2694. 10.1210/en.2002-221103, 12746333.
27. Kaplan EL, Meier PL. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 1958, 53:457-481.
28. Collett D. Modeling survival data in medical research 1994, New York: Chapman & Hall.
29. Liu JL, Yakar S, LeRoith D. Mice deficient in liver production of insulin-like growth factor I display sexual dimorphism in growth hormone-stimulated postnatal growth. Endocrinology 2000, 141:4436-4441. 10.1210/en.141.12.4436, 11108252.
30. Tang Z, Yu R, Lu Y, Parlow AF, Liu JL. Age-dependent onset of liver-specific IGF-I gene deficiency and its persistence in old age: implications for postnatal growth and insulin resistance in LID mice. Am J Physiol Endocrinol Metab 2005, 289:E288-295. 10.1152/ajpendo.00494.2004, 15769793.
31. Kleinberg DL, Wood TL, Furth PA, Lee AV. Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocr Rev 2009, 30:51-74.
32. Richards RG, Klotz DM, Walker MP, Diaugustine RP. Mammary gland branching morphogenesis is diminished in mice with a deficiency of insulin-like growth factor-I (IGF-I), but not in mice with a liver-specific deletion of IGF-I. Endocrinology 2004, 145:3106-3110. 10.1210/en.2003-1112, 15059953.
33. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007, 28:20-47.
34. Kleinberg DL. Role of IGF-I in normal mammary development. Breast Cancer Res Treat 1998, 47:201-208. 10.1023/A:1005998832636, 9516076.
35. Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado-Heinsohn E, Osborne CK, Yee D. Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol 1999, 13:787-796. 10.1210/me.13.5.787, 10319328.
36. Stewart AJ, Johnson MD, May FE, Westley BR. Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J Biol Chem 1990, 265:21172-21178.
37. Lee AV, Weng CN, Jackson JG, Yee D. Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. J Endocrinol 1997, 152:39-47. 10.1677/joe.0.1520039, 9014838.
38. Camirand A, Zakikhani M, Young F, Pollak M. Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Res 2005, 7:R570-579. 1175059, 15987464.